-
公开(公告)号:EP4136092A1
公开(公告)日:2023-02-22
申请号:EP21895589.6
申请日:2021-11-18
发明人: MULLICK, Adam , FREIER, Susan, M.
IPC分类号: C07H21/04 , C12N15/11 , C12N15/113
-
公开(公告)号:EP4110919A1
公开(公告)日:2023-01-04
申请号:EP21760424.8
申请日:2021-02-26
IPC分类号: C12N15/113 , C07H21/00 , A61K31/7125 , A61K31/712 , A61K31/7115
-
-
公开(公告)号:EP3917540A1
公开(公告)日:2021-12-08
申请号:EP20748816.4
申请日:2020-01-31
IPC分类号: A61K31/7088 , A61K31/712 , A61K31/7125 , A61P35/00 , C12N15/11 , C12N15/113
-
公开(公告)号:EP3822352A3
公开(公告)日:2021-11-03
申请号:EP20180985.2
申请日:2013-05-23
IPC分类号: C12N15/113 , A61P3/00 , A61P9/00 , A61P9/10 , A61P29/00
摘要: Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) or Lp(a). Certain diseases, disorders or conditions related to apo(a) or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The antisense compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
-
公开(公告)号:EP3899024A1
公开(公告)日:2021-10-27
申请号:EP19900290.8
申请日:2019-12-20
IPC分类号: C12Q1/68 , C12N15/113
-
公开(公告)号:EP3897837A1
公开(公告)日:2021-10-27
申请号:EP19899128.3
申请日:2019-12-20
IPC分类号: A61P25/02 , C12N15/11 , C12N15/113
-
公开(公告)号:EP3826645A1
公开(公告)日:2021-06-02
申请号:EP19841474.0
申请日:2019-07-25
IPC分类号: A61K31/712 , A61K31/7125 , C12N15/113
-
公开(公告)号:EP3799602A1
公开(公告)日:2021-04-07
申请号:EP19799466.8
申请日:2019-05-09
发明人: FREIER, Susan, M.
IPC分类号: C12N15/113
-
公开(公告)号:EP3757215A3
公开(公告)日:2021-03-17
申请号:EP20185802.4
申请日:2015-05-01
发明人: PRAKASH, Thazha, P. , SETH, Punit, P. , SWAYZE, Eric, E. , BHANOT, Sanjay , FREIER, Susan, M. , BUI, Huynh-Hoa
IPC分类号: C12N15/113 , C07H21/04 , A61K31/712 , A61K31/7125
摘要: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).
-
-
-
-
-
-
-
-
-